APA

Eisen T., Marais R., Affolter A., Lorigan P., Robert C., Corrie P., Ottensmeier C., Chevreau C., Chao D., Nathan P. D., Jouary T., Harries M., Negrier S., Montegriffo E., Ahmad T., Gibbens I., James M. G., Strauss U. P., Prendergast S. & Gore M. E. (20110916). Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. : British journal of cancer.

Chicago

Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan P D, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James M G, Strauss U P, Prendergast S and Gore M E. 20110916. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. : British journal of cancer.

Harvard

Eisen T., Marais R., Affolter A., Lorigan P., Robert C., Corrie P., Ottensmeier C., Chevreau C., Chao D., Nathan P. D., Jouary T., Harries M., Negrier S., Montegriffo E., Ahmad T., Gibbens I., James M. G., Strauss U. P., Prendergast S. and Gore M. E. (20110916). Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. : British journal of cancer.

MLA

Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan P D, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James M G, Strauss U P, Prendergast S and Gore M E. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. : British journal of cancer. 20110916.